Market
Vitamin B9 (commonly folic acid and its derivatives) is used in Russia primarily in dietary supplements marketed as biologically active additives to food (BAA), a product category subject to pre-market state registration and ongoing oversight. Market access and labeling obligations are anchored in Eurasian Economic Union (EAEU) technical regulations on food safety (TR CU 021/2011) and food labeling (TR CU 022/2011), alongside Russia’s Rospotrebnadzor state-registration processes and controls for BAA circulation. The most material trade constraint for cross-border supply into Russia is sanctions and export-control compliance (including payment, logistics, and counterparty screening constraints) rather than physical perishability. A secondary risk for the Russia market is enforcement exposure from falsified/misbranded dietary supplements (e.g., products found to contain undeclared pharmaceutical substances), making documentation-to-label consistency and batch-level quality evidence critical.
Market RoleImport-dependent consumer and manufacturing market (dietary supplements/BAA)
Domestic RoleDownstream market for supplement formulation/packing and retail distribution under state registration and EAEU technical regulation requirements
Risks
Sanctions And Export Controls HighSupplying vitamin B9 products into Russia can be blocked or severely disrupted by sanctions and export-control compliance constraints (counterparty restrictions, payment/settlement limitations, carrier/insurance constraints, and heightened circumvention scrutiny).Run end-to-end sanctions screening (counterparties, ownership, banks, logistics providers) and export-control checks; document legitimate end-use; use compliant routing/payment structures; obtain specialist legal/compliance review for the specific transaction.
Regulatory Compliance HighFinished dietary supplements (BAA) circulating in Russia are subject to state registration and labeling obligations; non-alignment between registration dossier, label claims, and batch documentation can trigger enforcement actions, delisting, or sales prohibition.Treat state registration and TR CU 022/2011 labeling as gating items before shipment/market placement; implement a label-to-dossier reconciliation and maintain batch documentation packages.
Quality Fraud MediumRospotrebnadzor communications document cases of falsified BAA that contained undeclared pharmaceutical substances and had registrations terminated, creating downstream recall and liability exposure for distributors and retailers.Require authenticated COA/quality documents per batch, perform risk-based third-party testing for identity and adulterants, and monitor Rospotrebnadzor notices affecting BAA registrations.
Logistics MediumEven for compact, high-value vitamin ingredients, Russia-related trade can face shipment delays and cost shocks due to restricted carrier options, insurance constraints, and rerouting needs under sanctions regimes.Qualify multiple forwarders/routes, build lead-time buffers, and pre-clear documentation to reduce port/terminal dwell time.
FAQ
Does a vitamin B9 dietary supplement need state registration to be sold in Russia?Yes. In Russia, biologically active additives to food (BAA) are subject to pre-market state registration and oversight by Rospotrebnadzor, and Rospotrebnadzor guidance indicates BAA should not be circulated or sold without state registration and the associated quality/safety documentation.
What are the main labeling and market-placement rules that typically apply to vitamin B9 supplements in Russia/EAEU?For products placed on the Russia market within the EAEU, TR CU 021/2011 frames food safety requirements and TR CU 022/2011 governs mandatory food labeling information (including Russian-language labeling in Russia). For dietary supplements (BAA), labeling and circulation should also align with the information agreed during state registration and related EAEU/Rospotrebnadzor controls.
What is the biggest trade-blocking risk when supplying vitamin B9 products into Russia?Sanctions and export-control compliance is the most critical risk: restrictions can block payments, logistics, or counterparties and create heightened enforcement exposure if screening and documentation are inadequate.